Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05859776 · ClinicalTrials.gov registry record · Phase 1

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

A Phase 1 study of Neovascular Age-related Macular Degeneration, sponsored by AsclepiX Therapeutics.

Active
Registry status
Phase 1
Development phase
15
Enrollment target
4
Study locations

NCT05859776: Active Phase 1 study of Neovascular Age-related Macular Degeneration, sponsored by AsclepiX Therapeutics.

NCT05859776 is a Phase 1 study of Neovascular Age-related Macular Degeneration that is active but no longer recruiting, run by AsclepiX Therapeutics. The registered enrollment target is 15 participants, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05859776, a Phase 1 study of Neovascular Age-related Macular Degeneration, is active but no longer recruiting, sponsored by AsclepiX Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
4
Study locations

Study Summary

The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question\[s\] it aims to answer are: * Safety of the maximum tolerable dose of AXT107 * Bioactivity and duration of action of AXT107 injected suprachoroidally Participants will be injected with AXT107 and will be followed on a regular monitoring visits through 9 months post single injection.

Conditions Studied

Neovascular Age-related Macular Degeneration

Interventions

  • DRUG AXT107 Low Dose
  • DRUG AXT107 Mid Dose
  • DRUG AXT107 High Dose

Study Locations (4)

Massachusetts

  • New England Retina Consultants - Springfield

Missouri

  • The Retina Institue - St Louis

North Carolina

  • Asheville Eye Associates - Asheville

Pennsylvania

  • Erie Retina Research - Erie

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2023-12-19
Est. Completion 2025-05
Phase Phase 1
AsclepiX Therapeutics

3 total trials

What the registry record for NCT05859776 still lists

NCT05859776 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which AXT107 Low Dose is the first listed.

NCT05859776 reports a single indexed study location in Massachusetts, Missouri, North Carolina.

Frequently Asked Questions

What is clinical trial NCT05859776 about?

NCT05859776 is a clinical study titled "Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)". The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question\[s\] it aims to answer are: * Safety of the maximum tolerable dose of AXT107 * Bioactivity and duration of action of AXT107 injected suprachoroidally Particip...

What is the current status of trial NCT05859776?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2023-12-19. Estimated completion is 2025-05.

What conditions does trial NCT05859776 study?

This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.

What interventions are being tested in trial NCT05859776?

The interventions under investigation include: AXT107 Low Dose (DRUG), AXT107 Mid Dose (DRUG), AXT107 High Dose (DRUG).

Who is sponsoring clinical trial NCT05859776?

This trial is sponsored by AsclepiX Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05859776 being conducted?

This trial has 4 study locations across Massachusetts, Missouri, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neovascular Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05859776's enrollment target sits among peer trials

15 33rd of 33 the lowest of 33 other Neovascular Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05859776, the US trial registry maintained by the National Library of Medicine. NCT05859776 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.